SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Siitonen M)
 

Sökning: WFRF:(Siitonen M) > (2020-2023) > T-cell acute lympho...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005972naa a2200673 4500
001oai:DiVA.org:uu-409967
003SwePub
008200505s2020 | |||||||||||000 ||eng|
009oai:DiVA.org:umu-169891
009oai:prod.swepub.kib.ki.se:143347418
009oai:gup.ub.gu.se/286616
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4099672 URI
0247 a https://doi.org/10.1038/s41375-019-0598-22 DOI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1698912 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1433474182 URI
0247 a https://gup.ub.gu.se/publication/2866162 URI
040 a (SwePub)uud (SwePub)umud (SwePub)kid (SwePub)gu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Quist-Paulsen, P.u Univ Trondheim Hosp, St Olavs Hosp, Dept Hematol, Trondheim, Norway.4 aut
2451 0a T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocol
264 c 2019-10-14
264 1b Springer Science and Business Media LLC,c 2020
338 a print2 rdacarrier
520 a The NOPHO ALL2008 is a population-based study using an unmodified pediatric protocol in patients 1-45 years of age with acute lymphoblastic leukemia. Patients with T-ALL were given a traditional pediatric scheme if fast responding (minimal residual disease (MRD) < 0.1% day 29), or intensive block-based chemotherapy if slow responding (MRD > 0.1% day 29). Both treatment arms included pediatric doses of high-dose methotrexate and asparaginase. If MRD >= 5% on day 29 or >= 0.1% after consolidation, patients were assigned to allogeneic hematopoietic stem cell transplantation. The 5-year overall survival of the 278 T-ALL patients was 0.75 (95% CI 0.69-0.81), being 0.82 (0.74-0.88) for patients 1.0-9.9 years, 0.76 (0.66-0.86) for those 10.0-17.9 years, and 0.65 (0.55-0.75) for the older patients. The risk of death in first remission was significantly higher in adults (12%) compared with the 1-9 years group (4%). The MRD responses in the three age groups were similar, and only a nonsignificant increase in relapse risk was found in adults. In conclusion, an unmodified pediatric protocol in patients 1-45 years is effective in all age groups. The traditional pediatric treatment schedule was safe for all patients, but the intensive block therapy led to a high toxic death rate in adults.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Pediatrik0 (SwePub)302212 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Pediatrics0 (SwePub)302212 hsv//eng
7001 a Toft, N.u Univ Copenhagen, Herlev Univ Hosp, Dept Hematol, Herlev, Denmark.4 aut
7001 a Heyman, M.u Karolinska Institutet4 aut
7001 a Abrahamsson, Jonas,d 1954u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för pediatrik,Institute of Clinical Sciences, Department of Pediatrics4 aut0 (Swepub:gu)xabrjo
7001 a Griskevicius, L.u Vilnius Univ, Vilnius Univ Hosp Santaros Klinikos, Hematol Oncol & Transfus Med Ctr, Vilnius, Lithuania.4 aut
7001 a Hallböök, Heleneu Uppsala universitet,Hematologi4 aut0 (Swepub:uu)helehall
7001 a Jonsson, O. G.u Landspitali Univ Hosp, Childrens Hosp, Reykjavik, Iceland.4 aut
7001 a Palk, K.u North Estonia Med Ctr, Dept Hematol, Tallinn, Estonia.4 aut
7001 a Vaitkeviciene, G.u Vilnius Univ, Vilnius Univ Hosp Santariskiu Klinikos, Childrens Hosp, Ctr Pediat Oncol & Hematol, Vilnius, Lithuania.4 aut
7001 a Vettenranta, K.u Helsinki Univ Cent Hosp, Hosp Children & Adolescents, Div Hematol Oncol & Stem Cell Transplantat, Helsinki, Finland.4 aut
7001 a Asberg, A.u Univ Trondheim Hosp, St Olavs Hosp, Dept Pediat, Trondheim, Norway.4 aut
7001 a Frandsen, T. L.u Rigshosp, Dept Pediat & Adolescent Med, Copenhagen, Denmark.4 aut
7001 a Opdahl, S.u NTNU, Fac Med & Hlth Sci, Dept Publ Hlth & Nursing, Trondheim, Norway.4 aut
7001 a Marquart, H. V.u Univ Hosp, Rigshosp, Dept Clin Immunol, Sect 7631, Copenhagen, Denmark.,Umea Univ, Dept Med Biosci Pathol, Umea, Sweden.4 aut
7001 a Siitonen, S.u Helsinki Univ Cent Hosp, Dept Clin Chem, Helsinki, Finland.4 aut
7001 a Osnes, L. T.u Oslo Univ Hosp, Dept Immunol, Oslo, Norway.4 aut
7001 a Hultdin, Magnusu Umeå universitet,Patologi4 aut0 (Swepub:umu)magn0001
7001 a Overgaard, U. M.u Univ Hosp, Rigshosp, Dept Hematol, Copenhagen, Denmark.4 aut
7001 a Wartiovaara-Kautto, U.u Helsinki Univ Hosp, Comprehens Canc Ctr, Dept Hematol, Helsinki, Finland.;Univ Helsinki, Helsinki, Finland.4 aut
7001 a Schmiegelow, K.u Rigshosp, Dept Pediat & Adolescent Med, Copenhagen, Denmark.;Univ Copenhagen, Fac Med, Inst Clin Med, Copenhagen, Denmark.4 aut
7102 a Univ Trondheim Hosp, St Olavs Hosp, Dept Hematol, Trondheim, Norway.b Univ Copenhagen, Herlev Univ Hosp, Dept Hematol, Herlev, Denmark.4 org
7730 t Leukemiad : Springer Science and Business Media LLCg 34:2, s. 347-357q 34:2<347-357x 0887-6924x 1476-5551
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-409967
8564 8u https://doi.org/10.1038/s41375-019-0598-2
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-169891
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:143347418
8564 8u https://gup.ub.gu.se/publication/286616

Hitta via bibliotek

  • Leukemia (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy